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Abstract (250 words) 
Objective: To assess the different treatment options for menopausal hormone 
therapy (HT) and the risk of breast cancer.  
Methods: Prospective Swedish nationwide cohort study including all women who 
received ≥1 HT prescription during the study period 2005-2012 (290,186 ever-users), 
group-level matched (1:3) to 870,165 never-users. HT, ascertained from the 
Prescribed Drug Register, was subdivided by estrogen and progestogen formulation 
types, regimens (continuous vs. sequential) and modes of administration (oral vs. 
transdermal). The risk of invasive breast cancer is presented as adjusted odds ratios 
(ORs) and 95% confidence intervals (CI).  
Results: Current use of estrogen-only therapy (ET) was associated with a slight 
excess breast cancer risk (OR=1.08, 95% CI 1.02-1.14). The risk for current estrogen 
plus progestogen (EPT) therapy was higher (OR=1.77, 95% CI 1.69-1.85) and 
increased with higher age at initiation; among women 70+ years the OR was 3.59 
(95% CI 3.30-3.91). In contrast, past use was associated with reduced breast cancer 
risk. Current continuous EPT use was associated with higher risk (OR=2.18, 95% CI 
1.99-2.40 for progesterone-derived; OR=2.66, 95% CI 2.49-2.84 for testosterone-
derived) than sequential use (OR=1.37, 95% CI 0.97-1.92 for progesterone-derived; 
OR=1.12, 95% CI 0.96-1.30 for testosterone-derived). The OR for current use was 
1.12 (95% CI 1.04-1.20) for estradiol, 0.76 (95% CI 0.69-0.84) for estriol, 4.47 (95% 
CI 2.67-7.48) for conjugated estrogens, and 1.68 (95% CI 1.51-1.87) for tibolone. 
Oral and cutaneous HT showed similar associations. 
Conclusions: Different HT regimens have profoundly different effects on breast 
cancer risk. This knowledge may guide clinical decision-making when HT is 
considered.  
Introduction 
Menopausal hormone therapy (HT) alleviates menopause-related symptoms and 
prevents osteoporotic fractures,1 but HT has been associated with an increased breast 
cancer risk.2 In two large prospective studies, short-term use of estrogen-only therapy 
(ET) did not increase the risk of breast cancer, yet longer-term use did.3, 4 Current 
recommendations state that HT for up to three to five years could be beneficial for 
women <60 years, while the excess risk of breast cancer in women >70 years is a 
relative contraindication,5 and that duration of HT should not exceed 3-5 years. 
 
It is well-established that adding progestogens to HT reduces the excess risk of 
endometrial cancer,6 however several studies suggest that estrogen+progestogen 
(EPT) formulations increase breast cancer risk.4, 7-11 Data are limited regarding the 
effects of different types of estrogens and progestogens, formulations, regimens and 
modes of administration of HT on breast cancer risk.2 Using cutaneous (patch) 
estrogens, which avoid the first-pass effect in the liver, may avoid the increased risk 
observed with oral use, but there is a need for studies examining this potential 
difference.  
 
After publication of a trial demonstrating an increased risk of breast cancer,12 use of 
HT has dropped dramatically over the last 15 years.13 The aims of this study were to 
assess the risk of breast cancer following contemporary HT while taking advantage of 
the wide range of HT regimens used in Sweden and to identify regimens that 
minimize any excess risk of breast cancer. 
   
 
Methods 
Cohort 
Since 1st July 2005, the Swedish Prescribed Drug Registry has recorded individual-
level data on all drugs prescribed and dispensed in Sweden with >99% 
completeness.14 Drugs dispensed over-the-counter and within hospitals are not 
included. Each record includes a Swedish personal identity number, individual 
characteristics, Anatomical Therapeutic and Chemical classification (ATC) codes, 
modes of administration, dates of prescribing and dispensing, and defined daily 
dosage (DDD) per package, i.e. “the assumed average maintenance dose per day for 
a drug used for its main indication in adults” as defined by the World Health 
Organisation.  
 
All women with at least one dispensed HT prescription between 1st July 2005 and 
31st December 2012 were identified.15 Ever HT-users were matched 1:3 on year of 
birth to women with no HT prescriptions. Both HT users and non-HT users were 
excluded if they were younger than 40 years, or if there was a history of malignancy 
(except non-melanoma skin cancer) identified from the Swedish Cancer Register 
(see below) at the time of their first HT prescription (users) or start of the study period 
(non-HT users). The group-level matching reduced model dependence and facilitated 
unbiased assessment of multiple outcomes.16 Women were first stratified on three 
binary variables which might influence prescription of HT: parity (parous/nulliparous), 
history of thrombotic events, and hysterectomy. Within each of these eight strata, 
ever HT users were matched to the “nearest neighbor” never HT user on year of 
birth, diabetes, obesity, smoking-related disorders, and alcohol-related disorders. 
Information on these variables was obtained from the discharge diagnoses in the 
Swedish Patient Registry (described below).  
 
Classification of menopausal hormone therapy 
The following HT formulation types (with ATC codes) were considered: estrogens 
(G03C), progestogens (G03D and G03C), and estrogens and progestogens (G03F, 
categorized as G03FA for fixed combinations and G03FB for sequential 
preparations). If persons were prescribed 1 progestogen HT during the study period, 
they were considered EPT users, otherwise ET users. Progestogens were subdivided 
into progesterone-derived (medroxyprogesterone) and testosterone-derived 
formulations (norethisterone, levonorgestrel, lynestrenol and dienogest).17 Estrogens 
were categorized as estradiol (G03CA01 and G03CA03), estriol (G03CA04), 
conjugated-estrogens (G03CA57), and tibolone (G03CX01). Persons switching HT 
types during the study period were excluded from the sub-analyses. For G03F EPT 
combinations, estradiol accounted for >99% of all prescriptions. We considered only 
systemic HT administration, i.e. oral or cutaneous excluding vaginal, which is not 
available over-the-counter in Sweden. Injectable HT is not used in Sweden. 
 
The duration of HT was estimated based on the DDD per package, taking potency of 
the drug and prescribed quantities into account as defined by the World Health 
Organization. The maximum allowed time covered by a prescription dispensation in 
Sweden is 3 months.14 Therefore, allowing for a wash-out period, current users were 
those with at least 1 dispensed prescription of HT during the last six months (180 
days) of follow-up. All the others were considered past-users. Because the 
Prescribed Drug Registry began July 1, 2005, HT prescriptions before that date were 
not available.  
 
The majority of the ever-users had at least one prescription in 2005 (N=173,465; 
59.8%) and had an unknown starting date of HT. An additional 12.1% women 
(N=35,090) prescribed HT entered in 2006, 6.8% in 2007 (N=19,640), 5.1% in 2008 
(N=14,860), and approximately 4% each year thereafter. To reduce misclassification 
(underestimation) of HT duration, the analyses based on person time focused on 
those with a first recorded prescription in 2006 onwards. A sensitivity analysis 
included only women without HT prescriptions in 2005 and 2006 and their first 
prescription in 2007 or later.  
 
Follow-up 
The personal identity number allowed linkage to the nationwide Swedish registries of 
cancer, patient data, and causes of death. The Swedish Cancer Registry, founded in 
1958 and more than 98% complete,18 was used to identify all incident invasive breast 
cancers. Estrogen receptor information is not available from the Registry. In the 
Swedish Patient Registry, with nationwide coverage of all in-hospitalizations since 
1987 and specialist out-patient care visits since 2001, diagnoses and surgical 
procedures are recorded. This registry was used to ascertain ever parous (based on 
record of delivery), hysterectomy, and co-morbidities that might confound the 
association between HT and breast cancer (e.g., osteoporosis, smoking-related 
diseases, alcohol related diseases, thrombotic events, obesity, and diabetes 
mellitus). The Swedish Causes of Death Registry, which was established in 1952 and 
is 100% complete, was used to collect date of death. The study was approved by 
Regional Ethical Review Board in Stockholm (2014/1291-31/4), and the need for 
informed consent was not required. 
 
Statistical analysis 
Conditional logistic regression, taking into account clustering by the exact-matching 
variables, was used for analyses evaluating ever use versus never use. Multivariable 
models were also adjusted for all 8 matching variables as well as osteoporosis, 
providing adjusted odds ratios (OR) and 95% confidence intervals (CIs). These 
analyses compared HT ever-users, current-users and past-users with never-users for 
the whole study period (2005-2012).  
To assess the relation between duration of HT and breast cancer risk, multivariable 
Cox regression models provided hazard ratios (HRs) and 95% CIs. Multivariable 
models were adjusted for the matching variables (using age at first prescription 
instead of year of birth), osteoporosis, duration of treatment, and formulations and 
regimens of HT if appropriate. Duration of HT (estimated by the total sum of DDD per 
package), was categorized as <12 month, 12-35 months, ≥36 months, using the <12 
months as reference group. Because the Prescribed Drug Registry began in July 
2005, we excluded individuals enrolled in 2005 (with uncertain start date of exposure) 
and cancers occurring within 12 months of enrolment for all Poisson models. Time of 
follow-up was calculated from the date of the first prescription, to the first cancer 
(breast or other types of cancer, i.e. competing risk), death, or end of the study period 
(December 31, 2012), whichever occurred first. All analyses were performed with 
Stata MP14 (Stata Corp). 
 
  
Results 
Descriptive characteristics 
The cohort included 290,186 ever-users of HT and 870,165 matched never-users. 
Age and other characteristics were equally distributed among HT users and never-
users (Table 1). ET was almost as common (46.9%, N=135,988) as EPT combination 
HT (53.1%, N=154,198). The primary mode of administration was oral (84.0%, 
N=243,682), while 12.3% (N=35,826) used cutaneous HT and 3.7% used both 
(N=10,678). Among ET users, the most common formulations of estrogen were 
estradiol (39.2%, N=53,339) and estriol (40.9%, N=55,653), followed by tibolone 
(13.2%, N=17,992) and conjugated-estrogens (0.9%, N=1,161).  
 
Among women using EPT, continuous EPT was more common (60.0%, N=92,381) 
than sequential combinations (18.3%, N=28,263). Additionally, testosterone-derived 
progestogens were administered more frequently (55.6%, N=85,659) than 
progestogen-derived progestogens (30.7%, N=47,308). The most commonly used 
EPT was testosterone-derived progestogens administered continuously (34.6%, 
N=53,360).  
 
Menopausal hormone therapy and overall risk of breast cancer  
Compared to never-users of HT, ever-users did not have an increased risk of breast 
cancer (OR=1.02; 95% CI 0.99-1.05) (Table 2). However, there were important 
differences in risk of breast cancer by type of formulation, age at initiation, as well as 
current versus past use. Compared to never-users, current users had an increased 
risk of breast cancer (OR=1.38, 95% CI 1.33-1.43), and the association was stronger 
for EPT users (OR=1.77, 95% CI 1.69-1.85) than ET users (OR=1.08, 95% CI 1.02-
1.14). Among current users of EPT, there was increasing risk of breast cancer with 
later age of initiation, and among women who began HT use at age 70 or later, 
current users of EPT had a more than threefold increased risk of breast cancer 
compared with never-users (OR=3.59, 95% CI 3.30-3.91). In contrast, past users of 
HT were at a decreased risk of breast cancer compared with never-users (OR=0.75, 
95% CI 0.72-0.79). This inverse association was stronger for past use of estrogen 
only HT (OR=0.63, 95% CI 0.60-0.67) than for EPT (OR=0.89, 95% CI 0.84-0.93).  
Duration of menopausal hormone therapy and risk of breast cancer  
The analyses of duration of HT were restricted to women with a first recorded 
prescription in 2006 (Table 3). Comparing ever-users exposed ≥12 months to those 
exposed <12 months, showed no increased risk of breast cancer (HR=1.03, 95% CI 
0.91-1.16). However, when examining specific HT types, the risk of breast cancer 
was increased among women using EPT ≥12 months (HR=1.17, 95% CI 1.00-1.38), 
but not for ET users (HR=0.89, 95% CI 0.74-1.07). Among current-users, the excess 
risk of breast cancer was highest among women younger than 60, especially among 
those using EPT for 12-35 months (HR=1.68, 95% CI 1.04-2.72). 
 
Estrogen-formulations of menopausal hormone therapy and risk of breast cancer 
Among estrogen only HT-users, different estrogen formulations were differentially 
associated with risk of breast cancer (Table 4). Ever-users of ET had an overall 
decreased risk of breast cancer compared to never-users (OR=0.83, 95% CI 0.80-
0.87), while current-users had a modestly increased risk (OR=1.08, 95% CI 1.02-
1.14). However, specific formulations of estrogens were associated with an increased 
risk of breast cancer. Ever-users of conjugated estrogens had a 33% increased risk 
(OR=1.33, 95% CI 1.00-1.77) and ever-users of tibolone had a 15% (OR=1.15, 95% 
CI 1.06-1.25) increased risk of breast cancer compared to never-users. The 
association was stronger among current-users of conjugated-estrogens (OR=4.47, 
95% CI 2.67-7.48) and tibolone (OR=1.68, 95% CI 1.51-1.87) although based on 
much smaller groups.  
 
Progestogen-formulations of menopausal hormone therapy and risk of breast cancer 
The risk of breast cancer for different formulations and usage-patterns of 
progestogens for women using combined EPT therapy is presented in Table 4. 
Compared to the never-users, risk of breast cancer was increased following ever 
continuous (daily) use of progestogens (OR=1.24, 95% CI 1.20-1.28). The risk was 
increased among users of continuous combinations of testosterone-derived 
progestogens (OR=1.63, 95% CI 1.55-1.71), but also progesterone-derived 
progestogens (OR=1.38, 95% CI 1.28- 1.48). In contrast, the sequential 
combinations of progestogens in ever-users were associated with either no increased 
risk or a reduced risk (Table 4). Among current-users, the magnitude of risks were 
higher among all progestogen-users, in particular for testosterone-derived continuous 
combinations (OR=2.66, 95% CI 2.49-2.84) and progesterone-derived continuous 
combinations (OR=2.18, 95% CI 1.99-2.40).  
 
Mode of menopausal hormone therapy administration and risk of breast cancer 
The associations between oral versus cutaneous HT and breast cancer are 
presented in Table 5. Descriptive frequencies of the types of oral and cutaneous 
hormone therapy are included in E3. Compared to never-users, the risk of breast 
cancer was highest among ever-users of oral HT (OR=1.44, 95% CI 1.39-1.50), 
especially among current-users of oral EPT (OR=1.86, 95% CI 1.77-1.95) (Table 5). 
Current cutaneous use of ET (OR=1.19, 95% CI 1.05-1.36) and EPT (OR=1.40, 95% 
CI 1.20-1.64) was also associated with an increased risk of breast cancer. Although 
there was heterogeneity in formulations of cutaneous regimens, the statistical power 
was insufficient to evaluate individual formulations.   
 
Discussion 
This study evaluating the association of contemporary menopausal hormone 
therapies with breast cancer risk showed that different HT regimens have different 
effects on breast cancer risk. As previous studies of older generations of HT have 
reported,4, 7, 19-21 this study found that current use of EPT was associated with an 
increased risk of breast cancer. Estrogen only HT was also associated with an 
increased risk, but the magnitude of association was much more modest.  
 
This study has a number of strengths, including the large sample size, population-
based study design, and contemporary formulations of HT. In addition, the Swedish 
Prescribed Drug Registry allowed for high quality and detailed information on HT 
formulations and nationwide coverage. The unique matched cohort design allowed 
for HT-users and non-users to be balanced on several potential confounders. This 
group-level matching enabled us to create two groups with a similar probability of 
being treated with HT, a similar approach as used in propensity-scoring matching, 
therefore limiting the risk of selection bias and confounding. This method also takes 
into account the problem with exposure time for never-users (who do not have a start 
date of exposure); yet the relative effect of duration of use was evaluated among 
different groups of HT users.   
This study also has some limitations. The main limitation is that the Swedish 
Prescribed Registry did not begin until 2005. This resulted in incomplete information 
on first date of prescription and as a result also incomplete data on duration of use. In 
secondary analyses, we restricted analyses to new prescriptions during the study 
period. In general, although the number of cases of breast cancer dropped, we found 
results that were very consistent with the main analysis. Additionally, we were limited 
in our ability to assess longer durations of use. Although older studies have 
demonstrated that longer duration of HT increases the risk of breast cancer, we could 
not assess this in the present cohort.  
 
We were also limited by availability of data coming from Swedish registries. We used 
the Patient Registry to control for potential confounders; however, we were unable to 
adjust for a number of known breast cancer risk factors such as reproductive factors 
and body mass index. Additionally, information on some factors such as 
hysterectomy and parity may be under ascertained for those occurring prior to the 
start of the registry, or may only reflect more severe cases (e.g. obesity). However, 
previous studies, which present both adjusted and unadjusted estimates suggest that 
confounding by established breast cancer risk factors is minimal.11 Additionally, we 
were unable to evaluate interactions between HT and factors such as body mass 
index and age at menopause, which others have reported with standard hormone 
therapy doses.4, 10 We were also unable to assess the association by family history, 
benign breast disease or tumor estrogen receptor (ER) status, since the Cancer 
Registry did not contain this information. A national mammography screening 
program has been established in 1994 in Sweden, inviting all women aged 40-74 
years every 18-24 months.22-24 Although approximately 80% attend the screening,23 
women on HT may be more likely to attend but no information on screening 
attendance was available.  Unfortunately we did not have information on the starting 
age of menopause25, in particular for the non-users. Among our HT users, 14.4% 
was younger than 50 at the time of their first prescription. Although we used age 40 
to avoid premature menopause, some non-users may not have started menopause 
yet giving them a higher probability of breast cancer compared to menopausal 
women of the same age.26 This may explain some of the apparent protective effects 
of HT in the younger age group. When those younger than 50 at the start of the study 
period were excluded, the risk of breast cancer among the youngest group of current 
users was OR=1.10 (95% CI 1.05-1.15) compared to OR=1.02 (95% CI 0.99-1.05) in 
the whole youngest age-group. 
 
Since the publication of WHI results in 2002, demonstrating an increased risk of 
breast cancer with EPT, prescription patterns for estrogen plus progestogen 
therapies have declined,27 and formulations and patterns of use have changed.28 The 
standard dose of estrogens in oral HT used in the WHI trial and prior to 2001 
included 0.625mg conjugated equine estrogens. Guidelines now recommend low-
dose and short-term use of oral HT.29, 30 Additionally, transdermal HT have also been 
advocated.31, 32 In line with these recommendations, the prevalence of women 
prescribed standard dose oral HT has declined in the US and Europe, while use of 
low-dose oral formulations as well as transdermal preparations have increased.33-37 
One of the main contributions of the current study is the ability to examine different 
types of estrogens and progestogens, formulations, regimens, and modes of 
administration. Combined EPT regimens with continuous progestogens were 
associated with a more than threefold increased risk compared to never users. In 
contrast, the sequential formulations were only suggestively associated with risk. 
These results have important public health implications. They suggest that for women 
interested in taking HT, sequential formulations are less associated with breast 
cancer risk compared to other EPT.  
 
We also found that current cutaneous use of EPT was associated with an increased 
risk of breast cancer. Although cutaneous use of EPT had a slightly lower risk than 
was observed with oral HT, this study provided much needed information on the risks 
associated with cutaneous HT. These findings argue against the hypothesis that 
cutaneous HT may not be associated with breast cancer to the same extent as oral 
HT since it avoids the first-pass effect in the liver (cutaneous estrogen may not 
increase sex hormone-binding globulin to the extent that oral preparations do).38 We 
also observed an inverse association with past use of HT, which is consistent with 
some prior studies,2, 11 but not all.20 It has been hypothesized that past-users are 
more likely to have shorter durations of use than current-users, and that these 
women may be using HT for the short-term relief of menopausal symptoms. 
Moreover, women who initiate HT tend to be leaner and may be at a reduced risk of 
developing breast cancer.39-41  
 
Conclusions 
In conclusion, this large population-based study found that risk of breast cancer 
differed substantially by various contemporary formulations of HT. These data fill 
important gaps in our knowledge and may help clinical decision-making when 
considering the benefits and potential harms of HT for relief of menopausal 
symptoms.  
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Table 1. Characteristics of all women (≥40 years) prescribed systemic 
menopausal hormone therapy (MHT) in Sweden between July 2005 and 
December 2012. 
  
  
Ever users of 
MHT 
Numbers (%) 
 
Ever users of estrogen 
MHT 
Numbers (%) 
 
Ever users of estrogen plus progestin 
MHT 
Numbers (%) 
 
Total 290,186 (100.0) 135,988 (46.9) 154,198 (53.1) 
Age at first prescription  
40-49 
years  46,299 (16.0) 14,196 (10.4) 32,103 (20.8) 
50-59 
years  127,773 (44.0) 43,385 (31.9) 84,388 (54.7) 
60-69 
years  59,592 (20.5) 28,887 (21.2) 30,705 (19.9) 
≥70 years  56,522 (19.5) 49,520 (36.4) 7,002 (4.5) 
 
Year of first prescription  
2005-2006  208,555 (71.9) 100,090 (73.6) 108,465 (70.3) 
2007-2009  46,736 (16.1) 20,553 (15.1) 26,183 (17.0) 
2010-2012  34,895 (12.0) 15,345 (11.3) 19,550 (12.7) 
 
 
 Table 2. The overall risk of cancer following systemic menopausal hormone therapy (MHT) use by MHT regimen and age at first 
prescription, expressed as standardized incidence ratios (SIR) and 95% confidence intervals (CI). 
                Absolute  
 
Number of 
observed  SIR (95% CI) p for  p for effect Excess number  
  
cases among 
exposed (%) All women <60 years 60-69 years ≥70 years trend modification 
of 
cases/100,000 
person-years 
ALL INCIDENT CANCERS 
        All MHT  16,813 (5.8) 1.09 (1.07-1.11) 1.08 (1.05-1.12) 1.09 (1.06-1.11) 1.10 (1.07-1.13) 0.00 0.00 212 
Estrogen only MHT  8,131 (6.0) 1.04 (1.01-1.06) 1.07 (1.01-1.13) 1.04 (1.00-1.08) 1.02 (0.99-1.06) 0.00 
  Estrogen plus progestin MHT  8,682 (5.6) 1.14 (1.12-1.17) 1.09 (1.05-1.13) 1.04 (1.01-1.08) 1.33 (1.26-1.40) 0.00 
  MAIN FEMALE REPRODUCTIVE ORGAN CANCERS 
       (Breast, endometrium, 
ovaries) 
        All MHT 8,160 (2.8) 1.31 (1.28-1.34) 1.00 (0.96-1.04) 1.48 (1.43-1.53) 1.57 (1.50-1.64) 0.00 0.00 159 
Estrogen only MHT  3,452 (2.5) 1.20 (1.16-1.24) 0.93 (0.86-1.00) 1.23 (1.16-1.31) 1.35 (1.28-1.43) 0.00 
  Estrogen plus progestin MHT  4,708 (3.1) 1.41 (1.37-1.45) 1.03 (0.98-1.09) 1.65 (1.58-1.73) 2.25 (2.08-2.42) 0.00 
  ALL GI TRACT CANCERS  
        (Esophagus+cardia, liver, gall and bile ducts, pancreas, gut, colon and 
rectum) 
      All MHT  2,436 (0.8) 0.90 (0.86-0.94) 0.97 (0.89-1.07) 0.90 (0.84-0.96) 0.87 (0.82-0.92) 0.00 0.00 -2 
Estrogen only MHT  1,399 (1.0) 0.91 (0.86-0.96) 1.02 (0.86-1.20) 0.95 (0.86-1.05) 0.88 (0.82-0.94) 0.00 
  Estrogen plus progestin MHT  1,037 (0.7) 0.88 (0.83-0.94) 0.93 (0.85-1.06) 0.86 (0.78-0.94) 0.84 (0.73-0.95) 0.00     
 
 
Table 3. The risk of breast and the main gynecological cancers following systemic menopausal hormone therapy (MHT) use by MHT 
regimen and age at first prescription, expressed standardized incidence ratios (SIR) and 95% confidence intervals (CI). 
                
 
Number of observed  SIR (95% CI) 
   
p for trend p for effect  
 Cases (%) All women <60 years 60-69 years ≥70 years 
 
modification 
BREAST CANCER 
       All MHT 6,376 (2.2) 1.24 (1.21-1.27) 1.13 (1.08-1.18) 1.32 (1.27-1.37) 1.28 (1.21-1.35) 0.00 0.00 
Estrogen only 2,548 (1.9) 1.05 (1.01-1.10) 1.09 (1.00-1.18) 1.09 (1.02-1.16) 1.00 (0.93-1.07) 0.14 
 Estrogen plus progestin 3,828 (2.5) 1.40 (1.36-1.45) 1.15 (1.09-1.21) 1.48 (1.41-1.55) 2.19 (2.01-2.37) 0.00 
 ENDOMETRIAL CANCER 
       All MHT 1,211 (0.4) 1.12 (1.06-1.19) 0.79 (0.68-0.91) 0.83 (0.75-0.92) 1.75 (1.61-1.90) 0.00 0.71 
Estrogen only 646 (0.5) 1.17 (1.08-1.27) 0.44 (0.30-0.62) 0.68 (0.57-0.82) 1.75 (1.59-1.92) 0.00 
 Estrogen plus progestin 565 (0.4) 1.07 (0.98-1.17) 0.94 (0.80-1.11) 0.94 (0.82-1.07) 1.78 (1.49-2.11) 0.00 
 OVARIAN CANCER 
       All MHT 573 (0.2) 1.09 (1.00-1.19) 1.13 (0.97-1.31) 0.99 (0.86-1.14) 1.22 (1.03-1.42) 0.00 0.18 
Estrogen only 258 (0.2) 1.03 (0.91-1.17) 1.02 (0.76-1.35) 0.87 (0.69-1.09) 1.18 (0.97-1.41) 0.00 
 Estrogen plus progestin 315 (0.2) 1.15 (1.03-1.29) 1.18 (0.98-1.41) 1.08 (0.90-1.28) 1.36 (0.97-1.85) 0.00  
 
 
 
 
 
 
Table 4. The risk of cancers of the gastrointestinal tract following systemic menopausal hormone therapy (MHT) use by MHT regimen 
and age at first prescription, expressed as standardized incidence ratios (SIR) and 95% confidence intervals (CI).  
                
 
Number of observed  
  
SIR (95% CI) 
 
p for trend p for effect  
 cases (%) All women <60 years 60-69 years ≥70 years 
 
modification 
ESOPHAGEAL CANCER (+CARDIA) 
      All MHT  86 (0.0) 0.81 (0.64-1.00) 0.53 (0.25-0.97) 0.75 (0.51-1.08) 0.99 (0.71-1.34) 0.00 0.47 
Estrogen only MHT 50 (0.0) 0.88 (0.65-1.16) 0.34 (0.04-1.21) 0.83 (0.46-1.40) 1.00 (0.68-1.41) 0.00 
 Estrogen plus progestin MHT 36 (0.0) 0.72 (0.50-1.02) 0.62 (0.27-1.21) 0.69 (0.40-1.13) 0.94 (0.43-1.79) 0.03 
 GASTRIC CANCER (-CARDIA) 
       All MHT  149 (0.1) 0.89 (0.75-1.05) 1.21 (0.85-1.67) 0.81 (0.58-1.10) 0.82 (0.63-1.04) 0.00 0.07 
Estrogen only MHT 83 (0.1) 0.84 (0.66-1.05) 0.73 (0.29-1.51) 0.67 (0.36-1.12) 0.91 (0.69-1.19) 0.00 
 Estrogen plus progestin MHT 66 (0.0) 0.96 (0.74-1.22) 1.42 (0.97-2.05) 0.91 (0.59-1.33) 0.50 (0.23-0.94) 0.01 
 PANCREAS CANCER  
       All MHT 311 (0.1) 0.94 (0.84-1.05) 1.03 (0.78-1.33) 0.87 (0.72-1.04) 0.98 (0.81-1.18) 0.00 0.00 
Estrogen only MHT 177 (0.1) 0.99 (0.84-1.15) 1.43 (0.93-2.12) 0.98 (0.74-1.27) 0.91 (0.72-1.21) 0.00 
 Estrogen plus progestin MHT 134 (0.1) 0.89 (0.74-1.05) 0.84 (0.57-1.18) 0.78 (0.60-1.00) 1.24 (0.86-1.72) 0.00 
 GALLBLADDER AND BILE DUCT CANCER  
      All MHT 129 (0.0) 0.88 (0.73-1.05) 1.23 (0.81-1.77) 0.72 (0.50-0.99) 0.89 (0.67-1.15) 0.00 0.62 
Estrogen only MHT 77 (0.1) 0.91 (0.71-1.15) 1.25 (0.60-2.37) 0.75 (0.43-1.22) 0.93 (0.68-1.24) 0.00 
 Estrogen plus progestin MHT 52 (0.0) 0.85 (0.63-1.11) 1.22 (0.73-1.90) 0.69 (0.42-1.06) 0.76 (0.38-1.36) 0.00 
 LIVER CANCER  
       All MTH 94 (0.0) 0.81 (0.65-0.99) 1.12 (0.72-1.65) 0.81 (0.56-1.11) 0.67 (0.45-0.95) 0.00 0.25 
Estrogen only MHT 49 (0.0) 0.77 (0.56-1.02) 1.29 (0.59-2.45) 0.80 (0.45-1.32) 0.65 (0.41-0.97) 0.01 
 Estrogen plus progestin MHT 45 (0.0) 0.86 (0.63-1.16) 1.04 (0.59-1.67) 0.81 (0.50-1.24) 0.74 (0.32-1.46) 0.00 
 COLON CANCER  
       All MHT  1,106 (0.38) 0.90 (0.84-0.95) 0.90 (0.77-1.05) 0.94 (0.85-1.04) 0.87 (0.80-0.95) 0.00 0.00 
Estrogen only MHT 660 (0.5) 0.91 (0.84-0.99) 0.91 (0.68-1.19) 0.97 (0.83-1.14) 0.89 (0.80-0.98) 0.00 
 Estrogen plus progestin MHT 446 (0.3) 0.88 (0.80-0.97) 0.90 (0.74-1.08) 0.92 (0.0-1.05) 0.80 (0.66-0.97) 0.00 
 RECTAL CANCER  
       All MHT  561 (0.2) 0.92 (0.84-1.00) 0.99 (0.83-1.17) 0.96 (0.83-1.10) 0.84 (0.72-0.97) 0.0000 0.00 
Estrogen only MHT 303 (0.2 0.99 (0.83-1.05) 1.08 (0.79-1.43) 1.06 (0.86-1.30) 0.83 (0.70-0.98) 0.0000 
 Estrogen plus progestin MHT 258 (0.2) 0.90 (0.79-1.02) 0.96 (0.77-1.17) 0.88 (0.72-1.06) 0.85 (0.62-1.15) 0.0000  
Table 5. The risk of other cancers following systemic menopausal hormone therapy (MHT) use by MHT regimen and age at first 
prescription, expressed as standardized incidence ratios (SIR) and 95% confidence intervals (CI).  
                
 
Number of observed  SIR (95% CI) p for trend p for effect  
 cases (%) All women <60 years 60-69 years ≥70 years 
 
modification 
LUNG CANCER  
       All MHT 1,333 (0.5) 1.07 (1.02-1.14) 1.25 (1.11-1.39) 1.05 (0.97-1.14) 0.99 (0.90-1.10) 0.00 0.00 
Estrogen only MHT  644 (0.5) 1.01 (0.93-1.10) 1.31 (1.07-1.59) 1.16 (1.03-1.31) 0.81 (0.71-0.92) 0.00 
 Estrogen plus progestin MHT  689 (0.4) 1.14 (1.05-1.23) 1.22 (1.05-1.40) 0.97 (0.87-1.09) 1.60 (1.35-1.89) 0.00 
 MALIGNANT MELANOM 
       All MHT 898 (0.3) 1.19 (1.11-1.27) 1.14 (1.01-1.27) 1.30 (1.16-1.44) 1.12 (0.98-1.28) 0.00 0.41 
Estrogen only MHT  454 (0.3) 1.26 (1.15-1.39) 1.13 (0.91-1.38) 1.40 (1.19-1.64) 1.23 (1.06-1.42) 0.00 
 Estrogen plus progestin MHT  444 (0.3) 1.13 (1.02-1.24) 1.14 (0.99-1.31) 1.22 (1.05-1.41) 0.76 (0.53-1.06) 0.00 
 TUMORS OF CENTRAL NERVOUS SYSTEM 
      All MHT 483 (0.1) 1.09 (0.99-1.20) 1.07 (0.91-1.24) 1.12 (0.97-1.29) 1.07 (0.86-1.32) 0.10 0.00 
Estrogen only MHT  220 (0.1) 1.08 (0.94-1.25) 1.20 (0.91-1.54) 1.11 (0.88-1.38) 0.97 (0.74-1.25) 0.03 
 Estrogen plus progestin MHT  263 (0.2) 1.09 (0.96-1.24) 1.01 (0.83-1.22) 1.13 (0.93-1.36) 1.41 (0.92-2.07) 0.00 
 KIDNEY CANCER (RENAL CELL) 
      All MHT  232 0.92 (0.80-1.04) 1.08 (0.82-1.40) 0.90 (0.72-1.10) 0.83 (0.65-1.05) 0.00 0.11 
Estrogen only 126 0.95 (0.79-1.14) 1.21 (0.74-1.87) 0.97 (0.69-1.31) 0.88 (0.66-1.13) 0.01 
 Estrogen plus progestin MHT  106 0.87 (0.71-1.06) 1.07 (0.72-1.40) 0.85 (0.63-1.12) 0.67 (0.36-1.14) 0.00 
 THYROID CANCER  
       All MHT 131 (0.0) 0.93 (0.77-1.11) 0.90 (0.67-1.18) 1.07 (0.78-1.43) 0.80 (0.51-1.19) 0.68 0.15 
Estrogen only MHT  72 (0.1) 1.15 (0.89-1.46) 1.41 (0.91-2.08) 1.30 (0.83-1.95) 0.83 (0.50-1.29) 0.29 
 Estrogen plus progestin MHT  59 (0.0) 0.75 (0.56-0.98) 0.67 (0.43-0.97) 0.90 (0.56-1.36) 0.71 (0.23-1.66) 0.31  
 
 
Supplementary Table 1. The risk of cancer following systemic menopausal hormone therapy (MHT) use by estrogen formulation, 
progestin type and regimen, and age at first prescription, expressed as standardized incidence ratios (SIR) and 95% confidence 
intervals (CI). 
                
 
Total number of  All  
All 
gastrointestinal  Breast  Ovarian  Endometrial  Colon  
  
exposed individuals 
(%) Cancers Cancers Cancer Cancer Cancer  Cancer 
Total number of cases in 
exposed 
 
16,813 2,436 6,376 573 1,211 1,106 
Only Estrogen Formulation 
       Estradiol 53,339 (39.2) 1.04 (1.00-1.08) 0.89 (0.80-0.99) 1.14 (1.08-1.22) 0.91 (0.72-1.13) 0.23 (0.16-0.31) 0.29 (0.24-0.35) 
Estriol 55,653 (40.9) 1.01 (0.98-1.05) 0.89 (0.83-0.96) 0.85 (0.79-0.92) 1.14 (0.93-1.37) 1.92 (1.75-2.11) 0.32 (0.28-0.37) 
Tibolone  17,992 (13.2) 1.14 (1.08-1.21) 1.00 (0.85-1.18) 1.36 (1.23-1.49) 0.94 (0.64-1.33) 1.51 (1.23-1.84) 0.38 (0.29-0.50) 
Estrogen plus Progestin Therapy 
       Progestin Regimen  
       Only continuous combinations 92,381 (59.9) 1.18 (1.15-1.21) 0.91 (0.85-0.98) 1.57 (1.51-1.63) 1.06 (0.91-1.22) 0.72 (0.63-0.82) 0.90 (0.81-1.01) 
Only sequential combinations 28,263 (18.3) 1.03 (0.96-1.10) 0.86 (0.69-1.05) 1.13 (1.02-1.25) 1.24 (0.88-1.70) 1.14 (0.87-1.47) 0.74 (0.51-1.04) 
Progestin Type  
       Only Progesterone-derived  47,308 (30.7) 1.14 (1.10-1.19) 0.81 (0.72-0.91) 1.41 (1.33-1.49) 1.23 (1.00-1.50) 1.35 (1.17-1.54) 0.88 (0.74-1.04) 
Only Testosterone-derived  85,659 (55.6) 1.19 (1.16-1.22) 0.96 (0.88-1.04) 1.52 (1.46-1.59) 1.20 (1.02-1.39) 0.87 (0.76-0.99) 0.91 (0.80-1.03) 
Progestin Regimen and Type  
       Progesterone-derived continuous  30,123 (19.5) 1.12 (1.07-1.17) 0.87 (0.75-0.99) 1.49 (1.39-1.60) 1.09 (0.83-1.41) 0.63 (0.48-0.80) 0.86 (0.69-1.06) 
Testosterone-derived continuous  53360 (34.6) 1.24 (1.20-1.28) 0.96 (0.87-0.98) 1.70 (1.62-1.78) 1.10 (0.91-1.33) 0.74 (0.63-0.87) 0.93 (0.81-1.07) 
Progesterone-derived sequential 3341 (2.2) 1.09 (0.91-1.29) 0.48 (0.21-0.95) 1.25 (0.95-1.60) 1.78 (0.77-3.51) 1.81 (0.99-3.04) 0.73 (0.24-1.70) 
Testosterone-derived sequential 21,247 (13.8) 1.05 (0.97-1.13) 0.97 (0.76-1.21) 1.17 (1.04-1.31) 1.24 (0.82-1.79) 0.85 (0.58-1.20) 0.79 (0.51-1.16) 
 
 
Supplementary Table 2. The association with estimated duration (based on the cumulative dosage per package) of systemic 
menopausal hormone therapy (MHT) use by MHT types, excluding women exposed in 2005, expressed as standardized incidence 
ratios (SIR) and 95% confidence intervals (CI). 
                
 
Total number of  All  All gastrointestinal  Breast  Ovarian  Endometrial Colon  
  
exposed individuals 
(%)  Cancers  Cancers  Cancer  Cancer Cancer   Cancer 
Total number of cases in 
exposed 
 
16,813 2,436 6,376 573 1,211 1,106 
Total, years  
       <1 58,801 (50.4) 0.97 (0.92-1.02) 0.85 (0.75-0.97) 0.91 (0.84-0.99) 1.12 (0.87-1.43) 1.07 (0.90-1.28) 0.92 (0.77-1.10) 
1  to 2 33,013 (28.3) 0.96 (0.90-1.02) 0.85 (0.72-1.00) 1.09 (0.99-1.20) 1.12 (0.81-1.51) 0.59 (0.43-0.80) 0.84 (0.64-1.08) 
3 to 4 12,403 (10.6) 0.71 (0.63-0.79) 0.61 (0.43-0.83) 0.73 (0.61-0.87) 0.44 (0.18-0.91) 0.38 (0.19-0.68) 0.59 (0.34-0.95) 
More than 5 12,504 (10.7) 0.48 (0.42-0.55) 0.39 (0.27-0.55) 0.37 (0.28-0.48) 0.13 (0.02-0.48) 0.56 (0.33-0.89) 0.38 (0.22-0.61) 
Only Estrogen, years  
       <1 28,389 (55.5) 1.01 (0.94-1.07) 0.65 (0.53-0.77) 0.92 (0.81-1.03) 1.14 (0.80-1.58) 1.00 (0.78-1.27) 1.00 (0.80-1.24) 
1  to 2 11,732 (22.9) 0.91 (0.82-1.00) 0.46 (0.32-0.63) 1.02 (0.87-1.20) 0.87 (0.46-1.48) 0.45 (0.25-0.75) 0.67 (0.43-0.99) 
3 to 4 3,308 (6.7) 0.65 (0.53-0.80) 0.26 (0.01-0.58) 0.59 (0.40-0.85) n=0 0.53 (0.17-1.23) 0.89 (0.41-1.68) 
More than 5 7,772 (15.2) 0.50 (0.42-0.59) 0.30 (0.18-0.46) 0.36 (0.24-0.52) 0.24 (0.03-0.85) 0.64 (0.34-1.09) 0.31 (0.15-0.57) 
Estrogen plus progestin, years  
       <1 30,412 (46.4) 0.92 (0.86-0.99) 0.94 (0.77-1.13) 0.91 (0.80-1.02) 1.07 (0.72-1.53) 1.17 (0.89-1.50) 0.78 (0.55-1.07) 
1  to 2 21,281 (32.5) 1.01 (0.93-1.09) 0.80 (0.62-1.00) 1.14 (1.01-1.29) 0.81 (0.48-1.27) 0.71 (0.48-1.02) 1.01 (0.71-1.39) 
3 to 4 9,095 (13.9) 0.73 (0.64-0.84) 0.41 (0.24-0.66) 0.78 (0.64-0.96) 0.54 (0.20-1.18) 0.31 (0.11-0.67) 0.41 (0.16-0.84) 
More than 5 4,732 (7.2) 0.45 (0.36-0.56) 0.32 (0.14-0.64) 0.38 (0.25-0.55) 0.15 (0.00-0.85) 0.43 (0.14-1.01) 0.10 (0.00-0.54) 
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Appendix 1. Cancer categorization by anatomical location using International 
Classification of Disease 10th edition (ICD-10). 
  ICD-10 
Breast and gynecological cancers  
 Breast C500-6, 8-9 
Endometrium C540-1, 3, 9; C559 
Ovaries C56; C570-4, 7-9 
Cancers of the gastrointestinal tract  
 Esophagus and cardia C150-5, 8-9, C160 
Gastric C161-6, 8-9 
Pancreas C250-4, 7-9 
Gallbladder and bile ducts C239; C240-1, 8-9 
Liver C220-1, 9 
Colon C180-9; C260,  
Rectum C199; C209; C21-2 
Other cancers  
Lung C339; C340-3, 8-9, C384, C398 
Malignant melanoma C430-9 
Central nervous system  C700-1, 9; C710-9; C720-5, 8-9; C752-3 
Bladder  C670-9 
Kidney  C64 
Thyroid  C739 
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Appendix 2. Sensitivity analysis by excluding the first calendar period (2005-
2006) for those cancers with the strongest associations by MHT types, 
expressed as standardized incidence ratios (SIR) and 95% confidence intervals 
(CI). 
      
 
SIR (95% CI) 
 
Years  Years  
2005-2012 2007-2012 
All incident cancers  
 
All MHT 1.09 (1.07-1.11) 1.12 (1.10-1.14) 
Estrogen MHT 1.04 (1.01-1.06) 1.07 (1.04-1.10) 
Estrogen plus progestin MHT 1.14 (1.12-1.17) 1.16 (1.14-1.19) 
All gastrointestinal cancers  
  
All MHT 0.90 (0.86-0.94) 0.93 (0.89-0.97) 
Estrogen MHT 0.91 (0.86-0.96) 0.95 (0.90-1.01) 
Estrogen plus progestin MHT 0.88 (0.83-0.94) 0.91 (0.85-0.97) 
Breast cancer  
  
All MHT 1.24 (1.21-1.27) 1.26 (1.22-1.29) 
Estrogen MHT 1.05 (1.01-1.10) 1.08 (1.03-1.13) 
Estrogen plus progestin MHT 1.40 (1.36-1.45) 1.40 (1.36-1.45) 
Endometrial cancer 
 
All MHT 1.12 (1.06-1.19) 1.15 (1.07-1.22) 
Estrogen MHT 1.17 (1.08-1.27) 1.19 (1.09-1.30) 
Estrogen plus progestin MHT 1.07 (0.98-1.17) 1.10 (1.00-1.21) 
Ovarian cancer 
  
All MHT 1.09 (1.00-1.19) 1.12 (1.02-1.23) 
Estrogen MHT 1.03 (0.91-1.17) 1.02 (0.88-1.17) 
Estrogen plus progestin MHT 1.15 (1.03-1.29) 1.22 (1.08-1.37) 
Colon cancer  
 
MHT 0.90 (0.84-0.95) 0.92 (0.86-0.98) 
Estrogen MHT 0.91 (0.84-0.99) 0.95 (0.86-1.02) 
Estrogen plus progestin MHT 0.88 (0.80-0.97) 0.91 (0.82-1.00) 
 
 
